Mineralocorticoid receptors in vascular disease: Connecting molecular pathways to clinical implications

Current Atherosclerosis Reports

Volumn 15, Issue 7, 2013, Pages

  McGraw, Adam P ^a   McCurley, Amy ^a   Preston, Ioana R ^a   Jaffe, Iris Z ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Atherosclerosis; Essential hypertension; Inflammation; Mineralocorticoid receptor; Pulmonary hypertension; Vascular remodeling; Vein graft failure

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL L TYPE; ENDOTHELIN B RECEPTOR; EPLERENONE; INTERCELLULAR ADHESION MOLECULE 1; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACEBO; PLACENTAL GROWTH FACTOR; SM 368229; SPIRONOLACTONE; TORCETRAPIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VOLTAGE GATED CALCIUM CHANNEL;

ALDOSTERONE BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; GRAFT FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; SYSTOLIC HYPERTENSION; UPREGULATION; VASCULAR DISEASE; VEIN GRAFT DISEASE; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE COURSE; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC; TRANSPLANTATION; VASCULAR DISEASES; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VEIN; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DRUG EFFECT; REVIEW;

ALDOSTERONE; ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, MINERALOCORTICOID; VASCULAR DISEASES; VEINS;

EID: 84878209241     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0340-x     Document Type: Article

References (96)

1. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids. 2000;65(2):61-73. (Pubitemid 30009768)
2. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932-40.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. (Pubitemid 36384098)
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. (Pubitemid 29407370)
5. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995- 1003. (Pubitemid 34286536)
7. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104(5):522-6. (Pubitemid 32738119)
8. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41(5):1021-6. (Pubitemid 36548598)
9. Hillaert MA, Lentjes EG, Kemperman H, et al. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.05.034.
10. de Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol. 2012;28(6):706-11.
11. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-8. (Pubitemid 40523144)
12. •• Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33(2):191-202. Prospective observational study demonstrating increased risk of cardiovascular ischemia and death in CAD patients with high serum aldo levels within the normal range.
13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22. (Pubitemid 350146106)
14. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153-60. (Pubitemid 47042895)
15. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304-16. (Pubitemid 46513296)
16. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118(24):2506-14.
17. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118(24):2515-22.
18. Duriez P. CETP inhibition. Lancet. 2007;370(9603):1882-3. (Pubitemid 350192639)
19. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204-12.
20. Janiczek RL, Blackman BR, Roy RJ, et al. Three-dimensional phase contrast angiography of the mouse aortic arch using spiral MRI. Magn Reson Med. 2011;66(5):1382-90.
21. Reneman RS, Arts T, Hoeks AP. Wall shear stress - an important determinant of endothelial cell function and structure - in the arterial system in vivo. Discrepancies with theory. J Vasc Res. 2006;43(3):251-69. (Pubitemid 44257044)
22. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121-8. (Pubitemid 43902687)
23. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109(18):2213-20. (Pubitemid 38625399)
24. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350(2):256-65.
25. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105(18):2212-6. (Pubitemid 34517167)
26. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41(6):955-63. (Pubitemid 36706146)
27. Gamliel-Lazarovich A, Gantman A, Coleman R, et al. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens. 2010;28(9):1900-7.
28. Raz-Pasteur A, Gamliel-Lazarovich A, Coleman R, Keidar S. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2012;60(6):508-12.
29. -/- mice. Endocrinology. 2011;152(1):236-46.
30. McGraw AP, Bagley J, Chen WS, et al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc. 2013;2:e000018.
31. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643-50. (Pubitemid 40478331)
32. Caprio M, Newfell BG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102(11):1359-67.
33. Dai G, Kaazempur-Mofrad MR, Natarajan S, et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci USA. 2004;101(41):14871-6. (Pubitemid 39410767)
34. Newfell BG, Iyer LK, Mohammad NN, et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol. 2011;31(8):1871-80.
35. Jaffe IZ, Tintut Y, Newfell BG, et al. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007;27(4):799-805. (Pubitemid 46606709)
36. • Jaffe IZ, Newfell BG, Aronovitz M, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010;120(11):3891-900. This manuscript identifies novel mechanism for aldosterone-induced vascular remodeling. Also shows that in human vessels, aldosterone & MR regulate the VEGF pathway that might contribute to vessel restenosis.
37. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120(9):3350-64.
38. Raz-Pasteur A, Gamliel-Lazarovich A, Gantman A, et al. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice. J Renin Angiotensin Aldosterone Syst. 2012. doi: 10.1177/1470320312467558.
39. Frieler RA, Meng H, Duan SZ, et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke. 2011;42(1):179-85.
40. Rickard AJ, Morgan JP, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54(3):537-43.
41. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest. 2013;123(1):27-36.
42. Tomaschitz A, Pilz S, Grammer T, et al. Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography. Exp Clin Endocrinol Diabetes. 2011;119(10):649-55.
43. Hillaert MA, Lentjes EG, Beygui F, et al. Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J. 2011;162(4):585-96.
44. Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160(4):642-8.
45. National Hospital Discharge Survey. 2010. Number, rate, and standard error of all-listed surgical and nonsurgical procedures for discharges from short-stay hospitals by selected procedure categories: United States, 2010. http://www.cdc.gov/nchs/data/nhds/4procedures/2010pro4-numberrate.pdf.
46. Sachs T, Pomposelli F, Hamdan A, et al. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. J Vasc Surg. 2011;54(4):1021-31.
47. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5(1):126-36. (Pubitemid 17000617)
48. Parang P, Arora R. Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol. 2009;25(2):e57-62.
49. Westerband A, Mills JL, Marek JM, et al. Immunocytochemical determination of cell type and proliferation rate in human vein graft stenoses. J Vasc Surg. 1997;25(1):64-73. (Pubitemid 27081610)
50. Hosono M, Ueda M, Suehiro S, et al. Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects: an immunohistochemical analysis. J Thorac Cardiovasc Surg. 2000;120(2):319-28. (Pubitemid 30640741)
51. Shukla N, Jeremy JY. Pathophysiology of saphenous vein graft failure: a brief overview of interventions. Curr Opin Pharmacol. 2012;12(2):114-20.
52. Bafford R, Sui XX, Park M, et al. Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization. Am J Physiol Heart Circ Physiol. 2011;301(1):H41-7.
53. • Ehsan A, McGraw AP, Aronovitz MJ, et al. Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice. J Thorac Cardiovasc Surg. 2012. doi: 10.1016/j.jtcvs.2012.08.007. First demonstration in a mouse model that MRA prevents vein graft remodeling.
54. Bacchetta MD, Salemi A, Milla F, et al. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites. Am J Ther. 2009;16(3):204-14.
55. Fu C, Yu P, Tao M, et al. Monocyte chemoattractant protein-1/CCR2 axis promotes vein graft neointimal hyperplasia through its signaling in graft-extrinsic cell populations. Arterioscler Thromb Vasc Biol. 2012;32(10):2418-26.
56. Moreno K, Murray-Wijelath J, Yagi M, et al. Circulating inflammatory cells are associated with vein graft stenosis. J Vasc Surg. 2011;54(4):1124-30.
57. Gromotowicz A, Szemraj J, Stankiewicz A, et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst. 2011;12(4):430-9.
58. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010;8, CD008169.
59. Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs. 2005;5(1):51-69.
60. Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol. 2009;301(1-2):2-6.
61. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplereneone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831-8. (Pubitemid 37296092)
62. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069-75.
63. Zhou X, Crook MF, Sharif-Rodriguez W, et al. Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. Clin Exp Hypertens. 2011;33(8):538-47.
64. Nagase M, Shibata S, Yoshida S, et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47(6):1084-93. (Pubitemid 44289165)
65. Baldo MP, Forechi L, Morra EA, et al. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep. 2011;63(4):975-82.
66. Sanz-Rosa D, Cediel E, de las Heras N, et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens. 2005;23(6):1167-72. (Pubitemid 40862720)
67. Baumann M, Megens R, Bartholome R, et al. Prehypertensive renin-angiotensin-aldosterone system blockade in spontaneously hypertensive rats ameliorates the loss of long-term vascular function. Hypertens Res. 2007;30(9):853-61. (Pubitemid 47578248)
68. Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37(2):662-7.
69. Nariai T, Fujita K, Mori M, et al. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J Cardiovasc Pharmacol. 2012;59(5):458-64.
70. Nariai T, Fujita K, Mori M, et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology. 2012;89(1-2):44-52.
71. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004;89(6):2736-40. (Pubitemid 38766358)
72. Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na + metabolism. Proc Natl Acad Sci USA. 1998;95(16):9424-9. (Pubitemid 28506247)
73. Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: lessons on Na + metabolism. Kidney Int. 2000;57(4):1295-8. (Pubitemid 30207881)
74. Ronzaud C, Loffing J, Bleich M, et al. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007;18(6):1679-87. (Pubitemid 46870305)
75. Ronzaud C, Loffing J, Gretz N, et al. Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am J Physiol Renal Physiol. 2011;300(3):F756-60.
76. Mendelsohn ME. In hypertension, the kidney is not always the heart of the matter. J Clin Invest. 2005;115(4):840-4. (Pubitemid 40489387)
77. Fujimura N, Noma K, Hata T, et al. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012;91(2):289-97.
78. • Maron BA, Zhang YY, White K, et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126(8):963-74. First demonstration in a rodent model that MRA prevents pulmonary hypertension.
79. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension. 2001;37(2 Pt 2):801-5. (Pubitemid 32199069)
80. Rossi R, Nuzzo A, Iaccarino D, et al. Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition. J Renin Angiotensin Aldosterone Syst. 2011;12(4):446-55.
81. Takeda Y. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res. 2009;32(5):321-4.
82. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24(7):2454-63.
83. •• McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429-33. Demonstrates a direct contribution of MR in smooth muscle cells to aging-associated hypertension. This manuscript alters the paradigm that MR regulates blood pressure exclusively by controlling renal sodium handling.
84. Mazak I, Fiebeler A, Muller DN, et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109(22):2792-800. (Pubitemid 38737927)
85. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76(9):834-9.
86. Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269(39):24316-20.
87. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension. 2004;44(3):340-5. (Pubitemid 39167233)
88. Luther JM, Luo P, Wang Z, et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int. 2012;82(6):643-51.
89. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41(7):1148-55. (Pubitemid 36384902)
90. Nakamura T, Fukuda M, Kataoka K, et al. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Hypertens Res. 2011;34(7):817-24.
91. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-56.
92. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Resp Crit Care Med. 2000;162(4 Pt 1):1577-86.
93. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115(10):2811-21. (Pubitemid 41434408)
94. Ross B, Giaid A. Role of endothelium in the development of pulmonary hypertension. In: Yuan JX-J, Garcia JGN, Hales CA, Rich S, Archer SL, West JB, editors. Textbook of pulmonary vascular disease. New York: Springer; 2011. p. 837-50.
95. Preston IR, Sagliani KD, Warburton RR, et al. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Phys Lung Cell Mol Phys. 2013. doi: 10.1152/ajplung.00300.2012.
96. Maron BA, Opotowsky AR, Landzberg MJ, et al. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. 2013;15(3):277-83.